Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children

Shirin Heidari, Lynne Mofenson, Mark F. Cotton, Richard Marlink, Pedro Cahn, Elly Katabira

Research output: Contribution to journalReview article

65 Citations (Scopus)

Abstract

The provision of antiretroviral drugs for the prevention of mother-to-child HIV transmission has been rising sharply in low- and middle-income countries. Changes to the World Health Organization guidelines support further extension of these programs. The result will be a greatly expanded population of HIV-exposed but uninfected children with substantial exposure to antiretroviral drugs, both in utero and while breastfeeding. There are limited data on possible toxicities in this burgeoning population, and the large number of confounding factors limits any conclusions. Although the evidence on birth defects and mitochondrial toxicity remains equivocal, considerable data link protease inhibitors to preterm delivery and low birth-weight. Transient hematologic toxicities are also likely. The drug impact later in life is an open question. Larger and longer cohort studies are necessary to properly balance the risks and benefits of large-scale infant exposure to antiretroviral agents.

Original languageEnglish (US)
Pages (from-to)290-296
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume57
Issue number4
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Mothers
HIV
Pharmaceutical Preparations
Anti-Retroviral Agents
Low Birth Weight Infant
Protease Inhibitors
Breast Feeding
Population
Cohort Studies
Guidelines

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{410f9b9a871043d4abfde86a1b19c3d1,
title = "Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children",
abstract = "The provision of antiretroviral drugs for the prevention of mother-to-child HIV transmission has been rising sharply in low- and middle-income countries. Changes to the World Health Organization guidelines support further extension of these programs. The result will be a greatly expanded population of HIV-exposed but uninfected children with substantial exposure to antiretroviral drugs, both in utero and while breastfeeding. There are limited data on possible toxicities in this burgeoning population, and the large number of confounding factors limits any conclusions. Although the evidence on birth defects and mitochondrial toxicity remains equivocal, considerable data link protease inhibitors to preterm delivery and low birth-weight. Transient hematologic toxicities are also likely. The drug impact later in life is an open question. Larger and longer cohort studies are necessary to properly balance the risks and benefits of large-scale infant exposure to antiretroviral agents.",
author = "Shirin Heidari and Lynne Mofenson and Cotton, {Mark F.} and Richard Marlink and Pedro Cahn and Elly Katabira",
year = "2011",
month = "8",
day = "1",
doi = "10.1097/QAI.0b013e318221c56a",
language = "English (US)",
volume = "57",
pages = "290--296",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Antiretroviral drugs for preventing mother-to-child transmission of HIV : A review of potential effects on HIV-exposed but uninfected children. / Heidari, Shirin; Mofenson, Lynne; Cotton, Mark F.; Marlink, Richard; Cahn, Pedro; Katabira, Elly.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 57, No. 4, 01.08.2011, p. 290-296.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antiretroviral drugs for preventing mother-to-child transmission of HIV

T2 - A review of potential effects on HIV-exposed but uninfected children

AU - Heidari, Shirin

AU - Mofenson, Lynne

AU - Cotton, Mark F.

AU - Marlink, Richard

AU - Cahn, Pedro

AU - Katabira, Elly

PY - 2011/8/1

Y1 - 2011/8/1

N2 - The provision of antiretroviral drugs for the prevention of mother-to-child HIV transmission has been rising sharply in low- and middle-income countries. Changes to the World Health Organization guidelines support further extension of these programs. The result will be a greatly expanded population of HIV-exposed but uninfected children with substantial exposure to antiretroviral drugs, both in utero and while breastfeeding. There are limited data on possible toxicities in this burgeoning population, and the large number of confounding factors limits any conclusions. Although the evidence on birth defects and mitochondrial toxicity remains equivocal, considerable data link protease inhibitors to preterm delivery and low birth-weight. Transient hematologic toxicities are also likely. The drug impact later in life is an open question. Larger and longer cohort studies are necessary to properly balance the risks and benefits of large-scale infant exposure to antiretroviral agents.

AB - The provision of antiretroviral drugs for the prevention of mother-to-child HIV transmission has been rising sharply in low- and middle-income countries. Changes to the World Health Organization guidelines support further extension of these programs. The result will be a greatly expanded population of HIV-exposed but uninfected children with substantial exposure to antiretroviral drugs, both in utero and while breastfeeding. There are limited data on possible toxicities in this burgeoning population, and the large number of confounding factors limits any conclusions. Although the evidence on birth defects and mitochondrial toxicity remains equivocal, considerable data link protease inhibitors to preterm delivery and low birth-weight. Transient hematologic toxicities are also likely. The drug impact later in life is an open question. Larger and longer cohort studies are necessary to properly balance the risks and benefits of large-scale infant exposure to antiretroviral agents.

UR - http://www.scopus.com/inward/record.url?scp=79959951684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959951684&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318221c56a

DO - 10.1097/QAI.0b013e318221c56a

M3 - Review article

C2 - 21602695

AN - SCOPUS:79959951684

VL - 57

SP - 290

EP - 296

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -